7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.1006/gyno.2001.6571
Copy DOIJournal: Gynecologic Oncology | Publication Date: Apr 1, 2002 |
Citations: 11 |
Objective. Antigene therapy targeting only one oncogene in ovarian cancer has made much progress, although it still has some limitations. To explore the potential for combination antigene therapy in ovarian cancer, we examined the in vitro effects of liposmal antisense phosphorothioate oligodeoxynucleotides targeting c-erbB2 and c-myc (LF–c-erbB2/c-myc AS-ODNs) in the human ovarian cancer COC1 cell line.Methods. COC1 cells were treated differently as follows: group A with single LF–c-erbB2 AS-ODNs; group B with single LF–c-myc AS-ODNs; group C with combination LF–c-erbB2/c-myc AS-ODNs; and group D as untreated control. Cell proliferation was studied by MTT assay and clonal cultures. RT-PCR was used to measure gene expression of c-erbB2 and c-myc before and after transfection. Morphologic changes in the COC1 cells were observed with the electron microscope.Results. Single antigene therapy targeting c-erbB2 or c-myc could reduce target gene expression and inhibit COC1 cell growth by 61.9 ± 9.3 and 64.5 ± 11.2%, respectively. However, combination antigene therapy could not only suppress expression of c-erbB2 and c-myc simultaneously, but also inhibit COC1 cell proliferation with a higher inhibitory rate of 82.6 ± 12.1%. Apart from that, the combination agents could induce COC1 cell apoptosis.Conclusions. Our study suggests that combination antigene therapy targeting c-erbB2 and c-myc can inhibit COC1 cell proliferation and gene expression of c-erbB2 and c-myc. Furthermore, its effectiveness is much higher than that of individual antigene therapy.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.